WHO clinical criteria-based initiation of antiretroviral therapy: lessons from rural district hospitals in Cameroon with regard to 2009 revised WHO recommendations

被引:7
作者
Kouanfack, Charles [2 ]
Laborde-Balen, Gabriele [3 ]
Aghokeng, Avelin F. [1 ,4 ]
Bourgeois, Anke [1 ,5 ]
Dontsop, Marlise [6 ]
Mben, Jean-Marc [6 ]
Kaze, Serge [6 ]
Mpoudi-Ngole, Eitel [4 ]
Koulla-Shiro, Sinata [2 ]
Delaporte, Eric [1 ,5 ]
Laurent, Christian [1 ]
机构
[1] Univ Montpellier 1, IRD, UMR 145, Montpellier, France
[2] Cent Hosp, Yaounde, Cameroon
[3] French Minist Foreign Affairs, Yaounde, Cameroon
[4] CRESAR IMPM IRD, Virol Lab, Yaounde, Cameroon
[5] Univ Hosp, Montpellier, France
[6] IRD, Yaounde, Cameroon
关键词
Africa; antiretroviral therapy; HIV; World Health Organization criteria; COHORT; HIV;
D O I
10.1111/j.1365-3156.2010.02495.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
P>Objective To assess the proportion of patients infected with HIV with a CD4 count above 350 cells/mm3 among those classified at WHO clinical stage 3 or 4 who initiated antiretroviral therapy in rural district hospitals in Cameroon to assess the 2009 revised WHO recommendations. Methods Cross-sectional study in nine rural district hospitals where the treatment initiation is based on the WHO clinical criteria. The proportion of patients who were classified at stage 3 or 4 and who had a CD4 count > 350 cells/mm3 was assessed. Results Of 458 patients included in 2006-2008 (women 70.5%; median age 37.0 years), 337 (73.6%) were classified at WHO clinical stage 3 and 121 (26.4%) at stage 4. Overall, 108 patients (23.6%) had a CD4 count > 350 cells/mm3. Of them, 94 patients (20.5%) were classified at WHO clinical stage 3, and 14 (3.1%) were classified at WHO clinical stage 4. Conclusion The WHO clinical stages 3 and 4 were poorly correlated with the 'gold standard' of CD4 cell count. This study highlights the need to promote CD4 testing for assessing the patient eligibility.
引用
收藏
页码:580 / 583
页数:4
相关论文
共 13 条
[1]  
[Anonymous], 2009, Progress Report'
[2]  
[Anonymous], 2006, UN ACC 2010 WHO IS W
[3]  
[Anonymous], DIR NAT PRIS CHARG P
[4]  
[Anonymous], PLAN DEC PRIS CHARG
[5]  
[Anonymous], 2009, Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents
[6]  
[Anonymous], 2006, ANT THER HIV INF AD
[7]  
Bourgeois A, 2005, ANTIVIR THER, V10, P335
[8]   Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda [J].
Jaffar S. ;
Birungi J. ;
Grosskurth H. ;
Amuron B. ;
Namara G. ;
Nabiryo C. ;
Coutinho A. .
AIDS Research and Therapy, 5 (1)
[9]   Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival [J].
Kitahata, Mari M. ;
Gange, Stephen J. ;
Abraham, Alison G. ;
Merriman, Barry ;
Saag, Michael S. ;
Justice, Amy C. ;
Hogg, Robert S. ;
Deeks, Steven G. ;
Eron, Joseph J. ;
Brooks, John T. ;
Rourke, Sean B. ;
Gill, M. John ;
Bosch, Ronald J. ;
Martin, Jeffrey N. ;
Klein, Marina B. ;
Jacobson, Lisa P. ;
Rodriguez, Benigno ;
Sterling, Timothy R. ;
Kirk, Gregory D. ;
Napravnik, Sonia ;
Rachlis, Anita R. ;
Calzavara, Liviana M. ;
Horberg, Michael A. ;
Silverberg, Michael J. ;
Gebo, Kelly A. ;
Goedert, James J. ;
Benson, Constance A. ;
Collier, Ann C. ;
Van Rompaey, Stephen E. ;
Crane, Heidi M. ;
McKaig, Rosemary G. ;
Lau, Bryan ;
Freeman, Aimee M. ;
Moore, Richard D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (18) :1815-1826
[10]   Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon:: open-label multicentre trial [J].
Laurent, C ;
Kouanfack, C ;
Koulla-Shiro, S ;
Nkoué, N ;
Bourgeois, A ;
Calmy, A ;
Lactuock, B ;
Nzeusseu, V ;
Mougnutou, R ;
Peytavin, G ;
Liégeois, F ;
Nerrienet, E ;
Tardy, M ;
Peeters, M ;
Andrieux-Meyer, I ;
Zekeng, L ;
Kazatchkine, M ;
Mpoudi-Ngolé, E ;
Delaporte, E .
LANCET, 2004, 364 (9428) :29-34